Anixa Biosciences, Inc.
ANIX · NASDAQ
10/31/2025 | 10/31/2024 | 10/31/2023 | 10/31/2022 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | -100% | – | – |
| Gross Profit | -$0 | $0 | $0 | $0 |
| % Margin | – | – | 23.3% | – |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | – | -5,221.4% | – |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | – | -4,671.9% | – |
| EPS Diluted | -0.34 | -0.39 | -0.32 | -0.45 |
| % Growth | 12.8% | -21.9% | 28.9% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |